antiretroviral therapy has been the selection of virus variants with mutations that lead to decreased drug susceptibility. Persons infected with drug-resistant HIV have decreased treatment options and can have poor therapeutic responses. Recent data suggest that new infection with a virus strain already resistant to antiretroviral drugs has a negative impact on initial treatment response and also shortens the time to first virological failure [2] . The transmission of HIV with mutations that confer antiretroviral resistance during the acute phase of HIV infection has been documented in numerous studies from many geographic areas where patients have ongoing access to antiretroviral medicines [3] [4] [5] [6] [7] [8] [9] . Most of these studies have focused on those with recent seroconversion to HIV. Little is known about how long resistance mutations acquired during primary infection persist in the plasma of patients with established infection who have not yet been exposed to antiretroviral drugs. A recent report that described 11 patients with transmitted resistant virus indicated that, after transmission of a virus bearing a K103N mutation, the average time to reversion of this mutation back to wildtype was 196 days, and no reversions were seen for protease inhibitor (PI) mutations out to 342 days [10] . Similarly, a study of 6 patients with primary resistance demonstrated no change in genotypic or phenotypic resistance to nonnucleoside reversetranscriptase inhibitors (NNRTIs) or PIs over a median of 12 months of follow-up and partial loss of resistance to nucleoside reverse-transcriptase inhibitors (NRTIs) in 3 persons [11] . Given these observations, a critical question in the field of HIV study is whether genotypic resistance testing is indicated for chronically infected, antiretroviral-naive patients preparing to initiate therapy. The current Department of Health and Human Services guidelines for antiretroviral therapy [12] do not generally recommend resistance testing for chronically infected, treatment-naive patients, primarily because of a lack of information concerning the prevalence of drug resistance in this population. They cite a prevalence of 5% as a possible level at which routine testing may be cost-effective [12] . The guidelines do recommend that genotypic resistance testing be considered for patients with acute infection. The International AIDS Society-USA recommends resistance testing for persons with established infections up to 2 years from the time of infection and possibly longer but, again, cite the lack of data to support testing in cases of chronic infection [13] . Most patients with new diagnoses who seek clinical care fit the definition of chronic HIV infection rather than that of acute infection, and the prevalence of resistance mutations among these patients needs elucidation.
The Terry Beirn Community Program for Clinical Research on AIDS (CPCRA), a multicenter network, began a treatment strategy trial for HIV-infected persons naive to treatment in 1999. The Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial (CPCRA 058) enrolled a cohort of 1397 demographically diverse treatment-naive subjects from 18 sites encompassing 25 US communities. A subset of baseline samples from the FIRST cohort was randomly selected and analyzed to determine the prevalence of primary drug resistance in this large, demographically diverse cohort of chronically infected patients, recruited over a 3-year period. The intent of this project was to inform the HIV clinical community regarding the necessity of routine resistance screening for such patients before initiation of antiretroviral therapy.
METHODS

Study design.
The CPCRA FIRST study is an ongoing, prospective, randomized trial that compares 3 treatment strategies for the initial treatment of antiretroviral-naive patients with HIV infection: 1-2 PIs plus NRTI, NNRTI plus NRTI, or PI plus an NNRTI plus 1 or 2 NRTIs. Treatment strategies were defined by classes of drugs, not by specific antiretrovirals. For each of the 3 strategy arms and before randomization, patients and their clinicians were given the option of either preselecting the particular drugs to be used in a class or indicating that they would allow additional randomizations to study-specific drugs within each class. Full details of the study design have been published elsewhere [14] . The FIRST study reached its target enrollment and closed to accrual on 11 January 2002, with 1397 patients enrolled. The FIRST study was approved by the institutional review boards at the institutions where the study is conducted, and written informed consent was obtained from all study participants.
Study population. HIV-infected persons who were у13 years of age, and who, in the cases of women with childbearing potential, were willing to use a barrier method of birth control throughout the course of the study, were eligible to participate. Patients were excluded for the following reasons: they were pregnant or breast-feeding or they had any conditions that precluded successful participation (in the judgment of the investigator), any previous PI or NNRTI use, a cumulative total of 14 weeks of NRTI use, or use of lamivudine for 11 week.
Data collection. Before randomization, a baseline evaluation was done that included medical and treatment history, physical examination, and determination of hepatitis B and C serostatus and previous diagnosis of AIDS-defining conditions, as well as obtainment of specimens for laboratory measures, such as CD4 cell count, HIV RNA level, and aspartate aminotransferase and alanine aminotransferase levels. A modified version of the previously published Centers for Disease Control and Prevention (CDC) criteria for AIDS-defining conditions was used [15] . Genotypic resistance tests were performed on stored specimens at a CPCRA-designated central laboratory, with plasma-derived viral RNA, by use of the TRUGENE HIV-1 genotyping kit and OpenGene DNA sequencing system [16] . The susceptibility to each drug was reported as susceptible, intermediate, or resistant, according to the CPCRA genotypic interpretive algorithm.
Statistical methods. Resistance was defined as the presence of у1 mutation on the basis of the International AIDS Society-USA 2003 definition [17] . Additional NRTI mutations that may represent back-revertants from earlier mutations at 215 C/D/ E/S and 69 A/N/S in the pol gene were also included [18] . Only mutations considered to be primary for the protease gene were included. These include mutations at positions 30, 46, 48, 50, 82, 84, and 90. For the baseline resistance analysis reported here, 504 baseline samples were randomly selected from the entire FIRST cohort, stratified by year of enrollment (1999, 2000 ). These 3 factors were chosen because of considerations about potential differences in time, region, and stage of infection. To establish a sample that represents completely treatment-naive subjects, patients with any antiretroviral use were excluded.
The percentage of patients from the sample with mutations was calculated. The prevalence of mutations for the cohort and corresponding 95% CI were estimated from the sample, by use of techniques for stratified random samples [19] . All results reported here are estimates of prevalence for the cohort. Simple and multiple logistic regression models were used to determine the factors associated with resistance. The following factors were included in the multiple logistic regression models: age, sex, ethnicity (non-Hispanic white vs. Hispanic and non-Hispanic white vs. African American), injection drug use, CD4 cell count (as a continuous variable), HIV RNA level (as a continuous variable, log 10 -transformed), previous diagnosis of AIDS-defining condition, year of enrollment, and geographic distribution.
RESULTS
Patient characteristics.
Among the 504 patients selected, 13 had used NRTIs and were excluded from the analysis. The characteristics of the remaining 491 patients are described in table 1. The average age was 38 years. Most of the patients were African American (52%); 16% were Hispanic. Nineteen percent of subjects were women. Overall, 15% had a history of injection drug use; 4% were positive for hepatitis B surface antigen, and 20% were coinfected with hepatitis C virus. Among the male subjects, 69% had sex with men. The mean CD4 cell count was 269 cells/mm 3 cells/mm 3 , and 31% of patients previously had an AIDSdefining event. In general, the characteristics of patients with mutations were not significantly different from those of patients without mutations. However, 42% of patients with mutations and 28% of those without mutations were nonHispanic white subjects ( ). P p .02 Prevalence of antiretroviral resistance mutations. Overall, 57 (11.6%) of the 491 patients sampled had у1 resistance mutation, resulting in an estimated prevalence for the cohort of 10.8% (95% CI, 9.5%-12.1%). By drug class, the estimated prevalence of mutations conferring resistance was 7.8% for NRTIs, 3.0% for NNRTIs, and 0.7% for PIs. Additionally, samples for 0.7% of patients were resistant to 11 class. Of the 57 patients with resistance mutations, 33 (58%) had a susceptibility interpretation of intermediate or resistant to у1 drug. If the 118I mutation, which has been associated with lamivudine resistance but can also occur as a natural polymorphism, was removed from the definition for resistance mutations for NRTIs, as reported in a recent study by the CDC [20] , then the estimated prevalence of mutations was 8.8% for any drug class and 5.6% for NRTIs.
Specific antiretroviral resistance mutations. The specific mutations observed are detailed in table 2. Note that, although no 184V mutations were observed, 17 patients had a 118I mutation, the most frequently observed amino acid change in this sample. Mutations at the 215 position of reverse transcriptase (RT), which have been associated with resistance to thymidine analogues, were also frequently seen (14 samples), as well as were revertants from 215Y, the most common 215 mutation associated with thymidine analogue resistance. Variants in the 69 position were also common, found in 12 samples. In addition, other thymidine analogue mutations observed were 41L, 44D, 70R, 210W, and 219Q. The K65R and I74V mutations were not observed. One patient had a combination of 151M, 70R, 77L, and 116Y mutations, associated with resistance to multiple drugs (data not shown). Other thymidine analogue mutations observed together in patients with multiple mutations were 70R, 69D, and 219Q in 1 patient and 41L and 210W in 2 patients. In the protease gene, multiple polymorphisms were observed, known to be naturally occurring, and are not reported here. However, 30N and 88D were observed together. The NNRTI mutations most often seen were 103N and 108I.
Factors associated with resistance mutations. In univariate analyses, there was a trend for increasing prevalence of mutations from 1999 to 2001 ( ) ( figure 1) . In a multiple P p .08 logistic regression model, there was a 40% increase per year in prevalence of mutations by later year of enrollment (adjusted OR, 1.4; 95% CI, 1.0-2.1;
). In addition, non-Hispanic P p .05 white subjects were more likely than African American subjects to have resistance (16.7% vs. 9.1%; adjusted OR, 2.1; 95% CI,
1.1-4.1;
). The percentage of Hispanic patients with P p .03 mutations was lower than the percentage of non-Hispanic white patients with mutations, but the difference was not significant (11.6% vs. 16.7%; OR, 0.6; 95% CI, 0.3-1.5;
). The P p .29 prevalence of resistance mutations did not differ by age, sex, injection drug use, CD4 cell count, HIV RNA level, previous diagnosis of AIDS-defining condition, or geographic distribution. Because there were too few patients ( ) with an n p 16 ethnicity other than non-Hispanic white, African American, or Hispanic, those patients were removed from the multiple logistic regression analysis.
DISCUSSION
This study provides one of the first descriptions of the prevalence of resistance to HIV drugs in chronically infected treatment-naive patients representing a geographically and racially diverse population in the United States. The results indicate that prevalence of mutations conferring antiretroviral resistance in chronically infected patients is common (10.8%) and that genotypic resistance testing of chronically infected patients before initiation of therapy may be appropriate. The population in this study had more advanced HIV disease and had a larger proportion of women than did previous studies and is representative of the ongoing epidemic of HIV infection in the United States and the type of HIV-infected patients who are currently presenting to care [21] .
The resistance mutations screened for in this study are the ones listed by the International AIDS Society-USA [17] and the ones used by the CDC in their recent resistance surveillance study of those newly converting to HIV [20] , with the exception of the 118I and 44D mutations. The 10.8% prevalence of resistance if all International AIDS Society-listed mutations were used or 8.8% if the 118I mutation was excluded is similar to the prevalence of 8.3% among persons with recent diagnoses observed in the CDC study and is surprisingly high for a population with advanced disease. Both exceed the 5% level suggested as a threshold at which genotypic resistance testing of all persons at baseline before initiation of therapy would be considered cost-effective [22] .
A disturbing-but not unexpected-observation was the increasing trend in prevalence by year of enrollment. In 2001, the last full year of study enrollment, the prevalence of any mutation was 14.7%. This implies that the current prevalence may well be higher than that observed during the 3 years that this study accrued patients. In a study by Little et al. [2] of persons with acute HIV infection that covered the period of 1995-2000, the prevalence of subjects with genotypic resistance mutations was 12%. They also observed an increased prevalence over time (8% in the period of 1995-1998 and 22% during 1999-2000) . Similarly, the prevalence of resistance among patients not recently infected was 9% in 1999 and 12% in 2000 in the CDC study, which is very similar to the prevalences in our study over a similar time period [20] . Both our study and the CDC report included a diverse group of participants with respect to sex, race, and risk factors. In the CDC study, for example, 46% of subjects were black, and 74% were male. In our study, 52% were black, 81% were male, and patients came from 25 US cities. Both studies showed a trend toward increasing prevalence with year of seroconversion or enrollment, although in our study, this trend reached statistical significance in the multivariate analysis.
We found that many of the mutant viral variants infecting these patients have persisted in the circulating viral quasi species, as have others [2, 20, [23] [24] [25] . The persistence of these mutations is of concern, because they increase the chance of secondary transmission of drug-resistant variants [10] . The lack of some mutations that are known to cause a decrease in replication capacity (e.g., M184V) in our patients may be explained by overgrowth of a more replication-competent variant [11, 26, 27] . Other reasons for the differences observed in transmitted mutations could be availability of antiretroviral therapy during the sample period or rates of exposure to compartmentalized resistant virus [28] .
The most prevalent mutations were in the NRTI class. This is not surprising, given that the population had a mean CD4 cell count of 269 cells/mm 3 , suggesting that many of these patients may have been infected for ∼7-8 years [29] . The NRTIs have been available longer than the other classes screened for in genotype resistance tests, and it would be expected that the greater length of exposure would lead to a higher prevalence of mutations.
Among the detected NRTI mutations, the thymidine analogue mutations were the most common. In addition, RT codon 215 changes known as revertants (e.g., C/S/D) were commonly observed and are indicative of a prior 215Y mutation [18] . These codon 215 substitutions have been associated with virological failure during treatment with HAART regimens that contained stavudine or zidovudine [30] .
In general, NNRTI and PI mutations were seen less frequently, possibly reflecting their later introduction into the antiretroviral armamentarium. However, 6 patients had the RT codon 103N mutation, which confers resistance to the entire class of NNRTIs and has been recently shown to persist for years as the dominant viral variant in patients acutely infected with a drug-resistant K103N strain [10] . Seven patients were found to have 108I mutations. Although this mutation is not associated with reduction in activity of NNRTIs, it is indicative of NNRTI selection pressure and therefore may serve as a marker for other more important, archived mutations. This principle applies to all detectable mutations; thus, the phenotypic interpretation provided with a genotype resistance test might underestimate the prevalence of resistance. The presence of minor NRTI and NNRTI mutations should raise suspicion of other archived mutations in the same class. In this respect, genotype testing will likely be more useful than phenotype testing at baseline.
A major strength of this study design is that it uses samples obtained from a large, clinical end point study. The resistance data will ultimately be applied to the clinical end points of the larger study, once completed and unblinded, to determine whether baseline resistance mutations have an impact on clinical outcomes.
A weakness of this study design was a lack of access to detuned assay (a modified HIV antibody assay used to indicate recent seroconversion) data to support the contention that the patients in this study were chronically infected. However, no difference in prevalence of mutations by CD4 cell count was observed in our study, which makes the impact of recent infections, if present, in this group less relevant. Additionally, in the CDC study by Weinstock et al. [20] , there was no difference in prevalence of resistance mutations by duration of infection on the basis of detuned assay testing. Last, the decision to perform resistance testing at baseline will be made by clinicians without the benefit of detuned assay results, and therefore, their judgment regarding resistance testing will more likely be guided by clinical data, as in our study.
In conclusion, the prevalence of primary HIV antiretroviral resistance in a chronically infected, geographically, racially, and sexually diverse group of patients with moderately advanced HIV disease is ∼9%-11% and appears to be increasing over time. These data support routine genotypic resistance testing of all treatment-naive patients before initiation of antiretroviral therapy. It is unknown whether this resistance will translate into slower treatment response rates and higher rates of treatment failure among chronically infected patients, but the increased number of treatment failures observed among newly infected patients undergoing treatment may portend a similar outcome for persons with more advanced disease [2, 3] . The FIRST study is a clinical end point trial comparing 3 treatment strategies for long-term outcomes, and this study, once completed, will be able to report the effect of primary resistance on clinical outcomes. Clinical management of treatment-naive, chronically HIV-infected patients in the United States will need to address the growing problem of primary HIV drug resistance.
